Engineered cellular carrier nanoerythrosomes as potential targeting vectors for anti-malarial drug

Jaya Agnihotri, Virendra Gajbhiye, Narendra Kumar Jain

Abstract


The present investigation was aimed at developing and exploring the use of nanoerythrosomes (nEs) for targeted delivery of anti-malarial drug, pyrimethamine (PMA). The formulation was prepared by the extrusion method and drug was conjugated to nEs with the help of gluteraldehyde used as a cross-linking agent. The nEs formulation was optimized for drug concentration, surface morphology, viscosity, and sedimentation volume. The drug-loaded nEs showed delayed in vitro release, good stability at 4±1°C, and controlled in vivo release. Tissue distribution studies showed higher accumulation of drug in liver (17.34±1.3 μg/ml) at 3 h in the case of nEs as compared to free drug (12.82±0.7 μg/ml). A higher amount of drug i.e. 13.14±0.9 μg/ml was found after 24 h in liver in the case of nEs as compared to free drug concentration of 9.72±0.5 μg/ml. Data showed that developed PMA-loaded nEs hold promise for targeting and controlling the release of drug and improve treatment of malaria.


Full Text:

PDF

References


World Malaria Report. WHO Expert Committee on malaria; Geneva,

Switzerland; 2008.

Farooq U, Mahajan RC. Drug resistance in malaria. J Vector Borne Dis

;41:45-53.

Molineaux L. Malaria and mortality: Some epidemiological

considerations. Ann Trop Med Parasitol 1997;91:811-25.

Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: Cerebral malaria, neurological sequelae, anemia, respiratory distress,hypoglycemia, and complications of pregnancy. Am J Trop Med Hyg 2001;64:57-67.

Rollo I. Resistance of Plasmodium falciparum to pyrimethamine. TransacRoyal Society Trop Med Hyg 1955; 49: 94-95.

Fullerton DS. Antimalarials. 8th ed. Wilson and Gisvold’s Text book of

Organic Medical and Pharmaceutical Chemistry. In: Doergae RF, editor.

Lippincott, Philadelphia. 1982. p. 205-6.

Jain S, Jain NK. Engineered erythrocytes as a drug delivery system.

Indian J Pharm Sci 1997;59:275-81.

Gaudreault RC, Gicquaud C, Poyet P. Nanoerythrosome as bioactive

agent carrier. US patent 5653999. Published date 5 August 1997.

DeLoach JR, Barton C. Circulating carrier erythrocytes: Slow-release

vehicle for an antileukemic drug, cytosine arabinoside. Am J Vet Res

;43:2210-2.

Jain S, Jain SK, Dixit VK. Erythrocytes based delivery of isoniazid:

Preparation and in vitro characterization. Indian Drugs 1995;32:471-6.

Jain S, Jain NK. Resealed erythrocytes as drug carriers. In: Jain NK, editor. Controlled and Novel Drug Delivery. New Delhi: CBS Publishers and

Distributors; 2002. p. 256-7.

Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, Gaudreault R.

Nanoerythrosomes, a new derivative of erythrocyte ghost: Preparation

and antineoplastic potential as drug carrier for daunorubicin.

Anticancer Res 1994;14:915-9.

Talwar N, Jain NK. Erythrocytes as carriers of primaquin preparation:

Characterization and evaluation. J Control Rel 1992;20:133-42.

Talwar N, Jain NK. Erythrocytes as carriers of metronidazole: In-Vitro

characterization. Drug Dev Ind Pharm 1992;18:1799-812.

Lejeune A, Poyet P, Gaudreault RC, Gicquaud C. Nanoerythrosomes, a

new derivative of erythrocyte ghost: III. Is phagocytosis involved in the

mechanism of action? Anticancer Res 1997;17:3599-603.

Minzi OM, Massele AY, Gustafsson LL, Ericsson O. Simple and

cost-effective liquid chromatographic method for determination

of pyrimethamine in whole blood samples dried on filter paper. J

Chromatogr B Analyt Technol Biomed Life Sci 2005;814:179-83.




DOI: http://dx.doi.org/10.22377/ajp.v4i2.134

Refbacks

  • There are currently no refbacks.